Part of our Year in Review series Of the 65 deals in Fierce Biotech’s 2023 Biotech M&A Tracker, psychedelics companies represented 3 (Cybin, Mindset, and Reunion). While that’s around 5% of the tracker’s sample size, the average deal value for psychedelics M&A was significantly lower than those seen in the broader biotech market, where many deals were measured in billions.As a reminder…

Source

Previous articlePT479 – Psilocybin in the Midwest and the Need for Potency Testing
Next articleThe Psychedelic News Feed: Dec 11 2023 – Jan 7, 2024